Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy
2015
WM is a disease of the elderly with a protracted course in many patients and a median survival of 7 to 10 years,[1][1] however, in many patients, other factors rather than WM or its treatment may be the cause of death.[2][2] Non-WM-related mortality mainly affects outcomes of elderly patients and is
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
15
References
27
Citations
NaN
KQI